THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 2 DATA

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will get ABBV-744 and ruxolitinib. Contributors will obtain treatment right up until condition progression or the individuals are unable to tolerate the study drugs.Celastrol was recognized being a Myb inhibitor that suppressed C/EBPβ action and repressed A